Sun Pharmaceutical Industries Limited · NSE:SUNPHARMA
Sun Pharmaceutical Industries — Investor Presentation (September 2026)
61 slides from Sun Pharmaceutical Industries's investor presentation, September 2026
Slide 1: Creating Lasting Value
Creating Lasting Value Investor Presentation – Sept 2026 NSE:SUNPHARMA | BSE:524715 | Bloomberg:SUNP IN | Reuters:SUN.BO WWW.SUNPHARMA.COM
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “pl
Slide 3: Sun Pharma
Sun Pharma 1 Revenue composition and growth highlights 2 Business operations 3 R&D & Manufacturing 4 Corporate Governance 5 Key Financials 6 Company history and key deals 7 Focus areas © Sun Pharmaceutical Industries Limited. All Rights Reserved. 3
Slide 4: Sun Pharma at a glance
Sun Pharma at a glance Leading global specialty generic company Global presence Operates in over 100 countries Diversified business Innovative Medicines, branded generics, generics & APIs Innovative Medicines Fast-growing. Focused therapy approach. US Generics 13th largest in US generics market## In
Slide 5: A diversified revenue base
A diversified revenue base Emerging Markets Rest of World (RoW)# Formulations Formulations 19% 15% API & Others 4% FY26 Sales Rs 582 Bn India Formulations 33% US Formulations 29% # Includes Western Europe, Canada, Japan, Australia & New Zealand, Israel and other markets. © Sun Pharmaceutical Industr
Slide 6: Impressive track record of growth
Impressive track record of growth (All Figures in Rs Bn) CAGR for FY11-FY26 177 582 124 332 279 82 85 59 Adjusted Sales EBITDA 52 Net Profit CAGR CAGR CAGR 57 17% 20 16% 18 14% FY11 FY16 FY21 FY26 FY11 FY16 FY21 FY26 FY11 FY16 FY21 FY26 52 124 88 Adjusted 67 62 Operating Free Cash 22 25 EPS Cash Flo
Slide 7: Strong profitability and return ratios
Strong profitability and return ratios Adjusted Net Profit Gross Margin # EBITDA Margin Margin 22.8% 79.3% 80.2% 30.3% 20.8% 21.2% 77.7% 19.8% 19.7% 75.4% 29.0% 73.1% 26.9% 26.9% 26.5% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 ROCE ROE Market Cap (USD Bn) 20.4% 20.7%
Slide 8: Best-in-class profitability
Best-in-class profitability Sun Pharma Range of Top 9 Indian Pharma Cos. Average Gross Margin EBITDA Margin Adjusted Net Profit Margin 79% 80% 78% 75% 30% 29% 68% 67% 27% 27% 66% 23% 63% 20% 21% 21% 26% 25% 25% 21% 18% 17% 16% 13% FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Gross mar
Slide 9: Business operations
Business operations © Sun Pharmaceutical Industries Limited. All Rights Reserved. 9
Slide 10: Snapshot of business operations
Snapshot of business operations US Formulations India Formulations FY26 sales: Rs 168,242 mn FY26 sales: Rs 192,904 mn Innovative Medicines & Generics. Over 600 approved Largest pharma company in India with 8.4% market products share Large part of Innovative Medicines sales in the US. No
Slide 11: Driving sustainable long-term growth
Driving sustainable long-term growth Balance profitability & Sustainable growth investments • Achieve critical mass in key markets • Increase contribution of Innovative and complex products • Embed sustainability practices in business • Direct future investments towards • Actionable targets on susta
Slide 12: ESG Performance - FY 2025-26
ESG Performance - FY 2025-26 Environmental Social Governance Energy Employee wellbeing Corporate Governance • 43% Energy sourced from • 8,727 new hires • 95.24% Average Board meeting renewable sources • 17.97% gender diversity attendance • 4.76% reduction in absolute Scope • 0 fatalities • 50% Indep
Slide 13: Innovative Medicines
Innovative Medicines © Sun Pharmaceutical Industries Limited. All Rights Reserved. 13
Slide 14: Innovative Medicines highlights
Innovative Medicines highlights Building an Innovative Medicines business in select therapy areas Marketed products in Dermatology, Ophthalmology and Onco Focused approach Dermatology Key growth driver 22% of sales in FY26 vs 7.3% of sales in FY18 Wide portfolio 29 products marketed globally US mark
Slide 15: Innovative Medicines portfolio
Innovative Medicines portfolio For treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy • Long term clinical data shows that the significant response rate seen in 52 & 64 weeks were maintained over five years1 • Completed Phase-3 trials
Slide 16: Innovative Medicines portfolio
Innovative Medicines portfolio Treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. • ODOMZO was shown to shrink laBCC in almost 6 out of 10 patients (5
Slide 17: Innovative Medicines portfolio
Innovative Medicines portfolio In combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). • YONSA® was shown in clinical studies to be an effective form of abiraterone acetate, and can be taken with or without food, in combinatio
Slide 18: Innovative Medicines pipeline
Innovative Medicines pipeline Candidate Mechanism Indication Pre- Phase 1 Phase 2 Phase 3 Registration of Action clinical Ilumya IL-23 Antagonist psoriatic arthritis Innovative soft tissue sarcoma Fibromun anti-cancer immunotherapy glioblastoma locally advanced melanoma Nidlegy Immunocytokines local
Slide 19: Innovative Medicines Sales
Innovative Medicines Sales Innovative Medicines Sales (USD mn) 674 871 1,039 1,216 1,420 • US is the major contributor to Innovative Medicines revenues • Global sales have grown by 24% 21.6 CAGR since FY21 19.8 18.0 • Largest product Ilumya reported 16.2 sales of $796 Mn in FY26 13.1 • 29 Innovative
Slide 20: US Business
US Business 29% of FY26 Revenues Powered by Bing © Australian Bureau of Statistics, GeoNames, Microsoft, Navinfo, Open Places, OpenStreetMap, Overture Maps Fundation, TomTom, Zenrin © Sun Pharmaceutical Industries Limited. All Rights Reserved. 20
Slide 21: US highlights
US highlights Sizeable innovative portfolio/13th largest in US Generics* Dermatology segment Ranked 2nd by prescriptions## in the US dermatology market Wide basket of 677 ANDAs & 70 NDAs filed, and 558 ANDAs & 57 Comprehensive portfolio** NDAs approved across multiple therapies Robust pipeline** 119
Slide 22: Milestones in the US business
Milestones in the US business FY26 • Launched Leqselvi & Unloxcyt • Acquired Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology FY25 company FY24 • Acquired outstanding shares of Taro, now a 100% subsidiary of Sun • Acquired Concert Pharma giving access to deuruxolitinib for alope
Slide 23: US business: revenue progression
US business: revenue progression Sales in Rs Bn 168 162 153 135 114 FY22 FY23 FY24 FY25 FY26 23
Slide 24: ANDA & NDA pipeline
ANDA & NDA pipeline ANDAs filed and approved (cumulative) NDA filed and approved (cumulative) 659 674 677 635 616 542 552 558 519 531 70 70 70 67 65 57 57 57 54 51 FY23 FY24 FY25 FY26 Q1FY27 FY23 FY24 FY25 FY26 Q1FY27 Cumulative products filed Cumulative products filed Cumulative products approved C
Slide 25: India Business
India Business 33% of FY26 Revenues © Sun Pharmaceutical Industries Limited. All Rights Reserved. 25
Slide 26: India highlights
India highlights Largest Pharma company in India Pharma market Market position** Largest Pharma company in India with 8.5% market share Prescription ranking## Ranked No. 1 by prescriptions with 12 classes of prescribers Chronic segment Market leader in the chronic segment Acute segment Strong positi
Slide 27: Largest Pharma company in India
Largest Pharma company in India Market Share Formulation sales in India as of 12 months ended June 2026 (Rs mn) 215,380 Sun Pharma 8.5% 148,510 Abbott + Abbott HC + Novo 5.9% 148,390 Cipla 5.8% 139,220 Mankind 5.5% 128,010 Torrent 5.0% 103,700 Alkem + Cachet + Indchemie 4.1% 101,870 Intas 4.0% 89,72
Slide 28: India: revenue progression
India: revenue progression Sales in Rs Bn Therapeutic breadth** Others Urology 3% 3% Opthalmology Neuro-Psychiatry 19% 193 3% Dermatology 169 4% Gynaecology 149 4% 136 Vitamins / Minerals / Nutrients 128 5% Cardiology Respiratory Market Share 17% 5% 8.5% Anti-Infectives 6% Pain / Analgesics 7% Gastr
Slide 29: Leadership across therapeutic areas
Leadership across therapeutic areas* Number 1 Ranking with 12 Doctor Categories* Prescription Ranking Specialist June ‘23 June ‘24 June ‘25 June ‘26 Psychiatrists 1 1 1 1 Neurologists 1 1 1 1 Cardiologists 1 1 1 1 Gastroenterologists 1 1 1 1 Diabetologists 1 1 1 1 Consulting Physicians 1 1 1 1 Derma
Slide 30: India: Best-in-class field force productivity
India: Best-in-class field force productivity Sales per medical representative (Rs mn) 11,149 12,692 13,984 15,109 16,767 • Well trained and scientifically oriented sales representatives team with strong performance track record 11.5 11.4 • Highest field force productivity 11.2 amongst key players i
Slide 31: Emerging Markets
Emerging Markets 19% of FY26 Revenues Powered by Bing © Australian Bureau of Statistics, GeoNames, Microsoft, Navinfo, Open Places, OpenStreetMap, Overture Maps Fundation, TomTom, Zenrin © Sun Pharmaceutical Industries Limited. All Rights Reserved. 31
Slide 32: Emerging Markets highlights
Emerging Markets highlights Leading Indian company in Emerging Markets Global footprint Presence in over 80 countries Focus markets Romania, Russia, South Africa, Brazil, Mexico Product portfolio Extensive basket of branded generics Customer focus Strong relationships with prescribers Sales force Ov
Slide 33: Rest of World (Western Europe, Canada, Japan, ANZ, Israel & other markets)
Rest of World (Western Europe, Canada, Japan, ANZ, Israel & other markets) 15% of FY26 Revenues Powered by Bing © Australian Bureau of Statistics, GeoNames, Microsoft, Navinfo, Open Places, OpenStreetMap, Overture Maps Fundation, TomTom, Zenrin © Sun Pharmaceutical Industries Limited. All Rights Res
Slide 34: Rest of World highlights
Rest of World highlights Amongst the leading Indian companies Market presence Western Europe, Canada, A&NZ, Japan, Israel and others Expanding basket includes innovative medicines, hospital & retail Product portfolio products Focus Development and commercialization of differentiated products • Distr
Slide 35: Global Consumer Healthcare
Global Consumer Healthcare 35
Slide 36: Global Consumer Healthcare highlights
Global Consumer Healthcare highlights An attractive opportunity India Amongst the leading consumer healthcare companies Global presence Presence in over 25+ countries India, Romania, South Africa, Nigeria, Myanmar, Ukraine, Poland, Markets of presence Thailand, Belarus, Kazakhstan, Nepal, Morocco, U
Slide 37: Active Pharmaceutical Ingredients (API)
Active Pharmaceutical Ingredients (API) 4% of FY26 Revenues © Sun Pharmaceutical Industries Limited. All Rights Reserved. 37
Slide 38: API highlights
API highlights Backward integration has strategic importance Backward integration provides cost competitiveness and supply Strategic importance reliability Customers Large generic and innovator companies Product portfolio Approximately 400+ APIs Pipeline development 10-20 APIs scaled up annually Reg
Slide 39: Research & Development
Research & Development © Sun Pharmaceutical Industries Limited. All Rights Reserved. 39
Slide 40: Research & Development
Research & Development Cumulative R&D spend of ~Rs 345 Bn to date R&D spend R&D spend at 6.1% of sales for FY26 Innovative Medicines R&D Global development capabilities incl. clinical trials Finished dosage development, biological support, chemistry and Generic capabilities new drug development Orga
Slide 41: R&D investments
R&D investments R&D investments Filings and approvals 5.8% 5.5% 6.7% 6.2% 6.1% ANDA NDA/BLA DMF/CEP Patents** 32.5 32.5 677 543 3,303 31.8 70 558 409 23.7 57 2,542 22.2 FY22 FY23 FY24 FY25 FY26 Filed Approved Filed Approved Filed Approved Filed Granted ** Excludes expired/abandoned patents R&D inves
Slide 42: Global Manufacturing
Global Manufacturing © Sun Pharmaceutical Industries Limited. All Rights Reserved. 42
Slide 43: Global Manufacturing highlights
Global Manufacturing highlights World Class manufacturing infrastructure 40 manufacturing facilities across India, the Americas, Asia, Africa, Extensive global footprint Australia and Europe Vertically integrated network across six continents enables high Integrated network quality, low cost and a q
Slide 44: Manufacturing facilities
Manufacturing facilities 40 manufacturing sites • Formulation • India: 12, US : 3, Bangladesh: 2 • Canada, Hungary, Israel, South Africa, Malaysia, Romania, Egypt, Nigeria, Morocco and Russia: 1 each • Capacities available for a variety of finished dosages • API • India: 8, Australia : 2, Israel : 1
Slide 45: Corporate governance
Corporate governance Sun Pharma’s Board of Directors comprises a strong and balanced leadership, with five out of nine members serving as independent directors. Lead Independent Independent Director Independent Director Independent Director Independent Director Director Dr. Pawan Goenka Gautam B. Do
Slide 46: Key Financials
Key Financials © Sun Pharmaceutical Industries Limited. All Rights Reserved. 46
Slide 47: Summary Financials
Summary Financials Market capitalisation Rs 4,545 Bn / US$48 Bn (as of 07th Sept 2026) ( All Figures in Rs mn ) FY22 YoY FY23 YoY FY24 YoY FY25 YoY FY26 YoY P&L Summary Sales 384,264 16% 432,789 13% 477,585 10% 520,412 9% 582,201 12% Gross Profit 280,749 14% 326,167 16% 370,958 14% 412,939 11% 466,7
Slide 48: Sales split
Sales split In Rs Bn Sales 384 433 478 520 582 24 23 86 22 72 22 67 112 21 60 94 55 86 79 67 168 162 153 135 114 169 193 128 136 149 FY22 FY23 FY24 FY25 FY26 India Formulations US Formulations Emerging Markets Rest of World API+Others © Sun Pharmaceutical Industries Limited. All Rights Reserved. 48
Slide 49: EBITDA trend
EBITDA trend In Rs Bn Sales 384 433 478 520 582 % of Sales 20.7% 19.8% 24.6% 22.3% 26.9% 19.2% 19.6% 19.7% 19.2% 19.0% 32.2% 32.6% 30.4% 32.3% 28.0% 26.9% 26.5% 26.9% 29.0% 30.3% FY22 FY23 FY24 FY25 FY26 EBITDA Other Expenditure Personnel Costs Material Costs © Sun Pharmaceutical Industries Limited.
Slide 50: Cash Flow & debt
Cash Flow & debt Net Cash from Operating Activities (Rs Bn) Free Cash Flow (Rs Bn) 140.7 119.4 121.4 124.2 99.3 88.1 89.8 74.9 49.6 28.7 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Gross Debt (Rs Bn) Net Cash (excluding debt) (Rs Bn) 62.0 301.4 267.9 40.8 199.8 28.5 149.4 123.8 18.7 9.3 FY22 F
Slide 51: Financial ratios
Financial ratios FY22 FY23 FY24 FY25 FY26 Growth (%) Sales 15.6 12.6 10.4 9.0 11.9 Gross Profit 14.4 16.2 13.7 11.3 13.0 EBITDA 22.5 12.0 11.8 17.3 16.1 Net Profit 12.7 158.9 13.0 14.1 5.0 Net Profit (Adjusted) 29.3 # 12.8 # 16.5 # 19.0 # 3.5 # Margins (%) Gross Margin 73.1 75.4 77.7 79.3 80.2 EBITD
Slide 52: Key Financials Q1 FY27
Key Financials Q1 FY27 ( All Figures in Rs mn ) Q1 FY27 Q1 FY26 CHANGE FY26 FY25 CHANGE Gross Sales 151,836 137,861 10.1% 582,201 520,413 11.9% Revenue from operation 152,999 138,514 10.5% 584,620 525,784 11.2% Gross Profit 122,204 101,784 20.1% 466,764 412,939 13.0% Gross Margin 80.5% 73.8% 77.7% 7
Slide 53: Sales split Q1 FY27
Sales split Q1 FY27 ( All Figures in Rs mn ) Q1 FY27 Q1 FY26 CHANGE FY26 FY25 CHANGE Formulation India 54,749 47,211 16.0% 192,904 169,230 14.0% US 40,419 40,452 -0.1% 168,242 162,403 3.6% Emerging Markets 29,456 25,531 15.4% 111,865 94,160 18.8% ROW # 20,686 18,736 10.4% 85,684 71,626 19.6% Sub-tot
Slide 54: Company history and key deals
Company history and key deals © Sun Pharmaceutical Industries Limited. All Rights Reserved. 54
Slide 55: Creating a global company over time
Creating a global company over time 1983 1994 2010 2012 2013 Acquired Dusa Began with 5 Acquired URL IPO – Rs 550 Mn Acquired Pharma products Taro raised 2019 2018 2016 2015 2014 Acquired Global Agreement with Acquired rights for Acquired Acquired InSite Merck for in- Ranbaxy Acquired Pola Cequa & B
Slide 56: Key deals & rationale
Key deals & rationale Year Deals Country Rationale 2026 Announced Organon & Co. acquisition Global Enhance global scale, add Women’s Health and biosimilers First and only US FDA-approved anti-PD-L1 treatment 2025 Checkpoint Therapeutics Inc. Global for metastatic or locally advanced (cSCC) Acquired
Slide 57: Key deals & rationale
Key deals & rationale Year Deals Country Rationale Out-licensing agreement with AstraZeneca UK for Mainland 2019 Commercialise oncology portfolio in Mainland China ready-to-use infusion oncology products China Licensing agreement with CMS for tildrakizumab, Greater 2019 Access to Greater China marke
Slide 58: Sun Pharma - focus areas
Sun Pharma - focus areas • Enhance share of innovative/branded business US business • Continue to focus on complex generics and high entry barrier segments • Ensure broad product offering to customers across multiple dosage forms • Focus on productivity enhancement India • Maintain leadership positi
Slide 59: Sun Pharma - focus areas
Sun Pharma - focus areas • Unwavering focus on sustainability, built on a legacy rooted in caring for people, communities and the planet. Sustainability • Committed to governance, community upliftment, access to affordable healthcare & environment conservation • Focus on developing complex products
Slide 60: Sun Pharma at a glance
Sun Pharma at a glance Leading global specialty generic company Global presence Operates in over 100 countries Diversified business Innovative Medicines, branded generics, generics & APIs Innovative Medicines Fast-growing. Focused therapy approach. US Generics 13th largest in US generics market## In
Slide 61: Thank You
For more information please contact Investors Thank You Dr. Abhishek Sharma Tel : +91 22 4324 4324, Xtn 2929 Tel Direct +91 22 4324 2929 abhi.sharma@sunpharma.com Corporate Address SUN HOUSE, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063 © 2017 Sun Pharmaceutical Industries
Sun Pharmaceutical Industries — Investor Presentation (September 2026) on 6ix